Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37:2315 81. S4.6-14. Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation. 2002;106:388 91. S4.6-15. Bibbins-Domingo K, US Preventive Services Task Force. Aspirin use for the primary prevention of cardiovascular disease and colorec- tal cancer: US Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2016;164:836 45. S4.6-16. ASCEND Study Collaborative Group, Bowman L, Mafham M, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379:1529 39. S4.6-17. Gaziano JM, Brotons C, Coppolecchia R, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, pla- cebo-controlled trial. Lancet. 2018;392:1036 46. S4.6-18. Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for primary pre- vention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific state- ment of the American Heart Association, and an expert consen- sus document of the American College of Cardiology Foundation. Circulation. 2010;121:2694 701. S4.6-19. Halvorsen S, Andreotti F, ten Berg JM, et al. Aspirin therapy in pri- mary cardiovascular disease prevention: a position paper of the European Society of Cardiology working group on thrombosis. J Am Coll Cardiol. 2014;64:319 27. S4.6-20. Mora S, Manson JE. Aspirin for primary prevention of atherosclerotic cardiovascular disease: advances in diagnosis and treatment. JAMA Intern Med. 2016;176:1195 204. S4.6-21. Miedema MD, Duprez DA, Misialek JR, et al. 